ORIGIN: no increased CV and cancer risk with Sanofi's Lantus in early diabetes
This article was originally published in Scrip
Executive Summary
Early use of Sanofi's Lantus (insulin glargine [rDNA] injection) in type 2 diabetes neither raised or lowered the risk of heart attacks, strokes, cancer or cardiovascular-related mortality, researchers found in a large, long-term study, details of which were unveiled at the American Diabetes Associationmeeting in Philadelphia.